RATIONALE: Many abused solvents share a profile of effects with classical antidepressants. For example, toluene, which is a representative and widely abused solvent, has been reported to increase both serotonin and noradrenaline levels in several brain areas after an acute exposure and to act as a noncompetitive antagonist of the glutamatergic N-methyl-D-aspartic acid (NMDA) receptor subtype. Therefore, it is possible that toluene could possess antidepressant-like actions. OBJECTIVE: To provide an initial screening of toluene's antidepressant-like actions in the forced swimming test (FST) and the tail suspension test (TST) in mice and to analyze its possible mechanism of action. MATERIALS AND METHODS: Two series of experiments were performed. In the first one, male animals were exposed to toluene (0, 500, 1,000, 2,000, or 4,000 ppm) in a static exposure chamber for 30 min, and immediately after, evaluated for antidepressant-like effects. The results were compared with those obtained from mice treated with the serotonergic antidepressant clomipramine (CMI), the noradrenergic antidepressant desipramine (DMI), and the glutamatergic antidepressants, ketamine and MK-801. In the second part, we analyzed the effect of a combined administration of a subeffective concentration of toluene with a suboptimal dose of the various antidepressants acting at different neurotransmitter systems. RESULTS: Toluene produced a concentration-dependent antidepressant-like action in the FST and TST and facilitated both MK-801 and ketamine antidepressant-like effects, but not those of DMI or CMI. CONCLUSIONS: Toluene has antidepressant-like effects that are synergized with NMDA receptor antagonists.
RATIONALE: Many abused solvents share a profile of effects with classical antidepressants. For example, toluene, which is a representative and widely abused solvent, has been reported to increase both serotonin and noradrenaline levels in several brain areas after an acute exposure and to act as a noncompetitive antagonist of the glutamatergic N-methyl-D-aspartic acid (NMDA) receptor subtype. Therefore, it is possible that toluene could possess antidepressant-like actions. OBJECTIVE: To provide an initial screening of toluene's antidepressant-like actions in the forced swimming test (FST) and the tail suspension test (TST) in mice and to analyze its possible mechanism of action. MATERIALS AND METHODS: Two series of experiments were performed. In the first one, male animals were exposed to toluene (0, 500, 1,000, 2,000, or 4,000 ppm) in a static exposure chamber for 30 min, and immediately after, evaluated for antidepressant-like effects. The results were compared with those obtained from mice treated with the serotonergic antidepressant clomipramine (CMI), the noradrenergic antidepressant desipramine (DMI), and the glutamatergic antidepressants, ketamine and MK-801. In the second part, we analyzed the effect of a combined administration of a subeffective concentration of toluene with a suboptimal dose of the various antidepressants acting at different neurotransmitter systems. RESULTS:Toluene produced a concentration-dependent antidepressant-like action in the FST and TST and facilitated both MK-801 and ketamine antidepressant-like effects, but not those of DMI or CMI. CONCLUSIONS:Toluene has antidepressant-like effects that are synergized with NMDA receptor antagonists.
Authors: Nancy Cervantes-Anaya; Gabriel Azpilcueta-Morales; Erika Estrada-Camarena; Daniela Ramírez Ortega; Veronica Pérez de la Cruz; Maria Eva González-Trujano; C López-Rubalcava Journal: Front Behav Neurosci Date: 2022-05-06 Impact factor: 3.617
Authors: Elmira Anderzhanova; Kathrin Hafner; Andreas J Genewsky; Azza Soliman; Max L Pöhlmann; Mathias V Schmidt; Robert Blum; Carsten T Wotjak; Nils C Gassen Journal: Neurobiol Stress Date: 2020-07-04
Authors: Michelle Kokkinou; Elaine E Irvine; David R Bonsall; Sridhar Natesan; Lisa A Wells; Mark Smith; Justyna Glegola; Eleanor J Paul; Kyoko Tossell; Mattia Veronese; Sanjay Khadayate; Nina Dedic; Seth C Hopkins; Mark A Ungless; Dominic J Withers; Oliver D Howes Journal: Mol Psychiatry Date: 2020-05-07 Impact factor: 13.437